FOI release

Freedom of Information request on the clinical study report for Amitriptyline 25 mg Film-coated Tablets (PL 13606/0251) (FOI 21/746).

Published 29 December 2021

20th July 2021

FOI 21/746

Dear

Thank you for your communication, dated 29 June 2021, in which you requested the clinical study report for Amitriptyline 25 mg Film-coated Tablets (PL 13606/0251).

Please note that a bioequivalence study was not required for the approval of the marketing authorisation application for Amitriptyline 25 mg Film-coated Tablets (PL 13606/0251). A biowaiver was accepted according to the criteria for BCS-based biowaivers, as outlined in the CHMP Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **).

For further information, please see the link below to the Public Assessment Report for Amitriptyline 10 mg, 25 mg and 50 mg Film-coated Tablets (PL 13606/0250-0252).

https://mhraproducts4853.blob.core.windows.net/docs/5f89e66128de5d40db7502215109cb2c234a0288

I now consider this request closed. If you require any further information, please respond to the FOI Licensing Team at [email protected].

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: [email protected].

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely,

The FOI Licensing Team